EndoGastric Solutions, Inc. Announces Second Randomized Controlled Trial Comparing TIF Procedure to PPI Therapy for the Treatment of GERD

Published: Jun 28, 2012

REDWOOD CITY, Calif.--(BUSINESS WIRE)--EndoGastric Solutions® (EGS), the leader in endoluminal treatment of Gastroesophageal Reflux Disease (GERD), today announced the start of the TIF versus Medical Proton Pump Inhibitor (PPI) Management of Refractory GERD Symptoms (TEMPO) trial. TEMPO, the second in a series of randomized trials involving TIF, is designed to assess the safety and efficacy of the procedure—performed using EndoGastric Solutions’ EsophyX® device—as compared to PPI therapy to treat bothersome symptoms associated with chronic GERD.

Back to news